CYTOMX THERAPEUTICS INC (CTMX)

US23284F1057 - Common Stock

0.9269  -0.06 (-5.69%)

Fundamental Rating

3

CTMX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. CTMX may be in some trouble as it scores bad on both profitability and health. CTMX is valied quite expensively at the moment, while it does show a decent growth rate.



3

1. Profitability

1.1 Basic Checks

CTMX had positive earnings in the past year.
CTMX had a negative operating cash flow in the past year.
CTMX had negative earnings in each of the past 5 years.
CTMX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

CTMX's Return On Assets of 9.95% is amongst the best of the industry. CTMX outperforms 96.04% of its industry peers.
CTMX's Return On Invested Capital of 26.84% is amongst the best of the industry. CTMX outperforms 99.64% of its industry peers.
Industry RankSector Rank
ROA 9.95%
ROE N/A
ROIC 26.84%
ROA(3y)-24.16%
ROA(5y)-22.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CTMX's Profit Margin of 10.92% is amongst the best of the industry. CTMX outperforms 95.14% of its industry peers.
CTMX has a better Operating Margin (5.30%) than 94.41% of its industry peers.
Industry RankSector Rank
OM 5.3%
PM (TTM) 10.92%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CTMX is creating value.
Compared to 1 year ago, CTMX has more shares outstanding
The number of shares outstanding for CTMX has been increased compared to 5 years ago.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -5.76, we must say that CTMX is in the distress zone and has some risk of bankruptcy.
CTMX's Altman-Z score of -5.76 is on the low side compared to the rest of the industry. CTMX is outperformed by 65.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.76
ROIC/WACC2.52
WACC10.67%

2.3 Liquidity

CTMX has a Current Ratio of 1.04. This is a normal value and indicates that CTMX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CTMX (1.04) is worse than 88.11% of its industry peers.
CTMX has a Quick Ratio of 1.04. This is a normal value and indicates that CTMX is financially healthy and should not expect problems in meeting its short term obligations.
CTMX has a Quick ratio of 1.04. This is amonst the worse of the industry: CTMX underperforms 86.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.04

4

3. Growth

3.1 Past

CTMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 136.96%, which is quite impressive.
Looking at the last year, CTMX shows a very strong growth in Revenue. The Revenue has grown by 67.59%.
CTMX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.21% yearly.
EPS 1Y (TTM)136.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)67.59%
Revenue growth 3Y0.27%
Revenue growth 5Y11.21%
Sales Q2Q%26.71%

3.2 Future

CTMX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
Based on estimates for the next years, CTMX will show a decrease in Revenue. The Revenue will decrease by -0.45% on average per year.
EPS Next Y-118.59%
EPS Next 2Y-369%
EPS Next 3Y-238.87%
EPS Next 5Y14.87%
Revenue Next Year27.18%
Revenue Next 2Y-8.21%
Revenue Next 3Y-29.38%
Revenue Next 5Y-0.45%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 5.45, the valuation of CTMX can be described as very cheap.
Based on the Price/Earnings ratio, CTMX is valued cheaply inside the industry as 98.92% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of CTMX to the average of the S&P500 Index (27.34), we can say CTMX is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 5.45
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -13.78

4.3 Compensation for Growth

CTMX's earnings are expected to decrease with -238.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-369%
EPS Next 3Y-238.87%

0

5. Dividend

5.1 Amount

CTMX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (1/10/2025, 9:55:34 AM)

0.9269

-0.06 (-5.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners72.34%
Inst Owner Change0%
Ins Owners1.12%
Ins Owner Change1.73%
Market Cap72.54M
Analysts80
Price Target5.39 (481.51%)
Short Float %7.16%
Short Ratio4.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.57%
Min EPS beat(2)45.28%
Max EPS beat(2)139.87%
EPS beat(4)4
Avg EPS beat(4)155.17%
Min EPS beat(4)45.28%
Max EPS beat(4)301.21%
EPS beat(8)7
Avg EPS beat(8)100.82%
EPS beat(12)8
Avg EPS beat(12)62.89%
EPS beat(16)11
Avg EPS beat(16)51.05%
Revenue beat(2)2
Avg Revenue beat(2)55.14%
Min Revenue beat(2)23.14%
Max Revenue beat(2)87.14%
Revenue beat(4)4
Avg Revenue beat(4)55.97%
Min Revenue beat(4)23.14%
Max Revenue beat(4)89.65%
Revenue beat(8)7
Avg Revenue beat(8)38.03%
Revenue beat(12)7
Avg Revenue beat(12)2.3%
Revenue beat(16)9
Avg Revenue beat(16)1.46%
PT rev (1m)0%
PT rev (3m)-0.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-59.74%
EPS NY rev (1m)17.05%
EPS NY rev (3m)86.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20.19%
Valuation
Industry RankSector Rank
PE 5.45
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -13.78
EPS(TTM)0.17
EY18.34%
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS1.62
BVpS-0.3
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.95%
ROE N/A
ROCE 33.97%
ROIC 26.84%
ROICexc N/A
ROICexgc N/A
OM 5.3%
PM (TTM) 10.92%
GM N/A
FCFM N/A
ROA(3y)-24.16%
ROA(5y)-22.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 25.68%
Cap/Sales 0.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.04
Altman-Z -5.76
F-Score5
WACC10.67%
ROIC/WACC2.52
Cap/Depr(3y)56.24%
Cap/Depr(5y)79.07%
Cap/Sales(3y)2.77%
Cap/Sales(5y)3.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-118.59%
EPS Next 2Y-369%
EPS Next 3Y-238.87%
EPS Next 5Y14.87%
Revenue 1Y (TTM)67.59%
Revenue growth 3Y0.27%
Revenue growth 5Y11.21%
Sales Q2Q%26.71%
Revenue Next Year27.18%
Revenue Next 2Y-8.21%
Revenue Next 3Y-29.38%
Revenue Next 5Y-0.45%
EBIT growth 1Y119.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.23%
OCF growth 3YN/A
OCF growth 5YN/A